Enanta Pharmaceuticals, Inc. (ENTA) Market Cap & Valuation Ratios
Enanta Pharmaceuticals, Inc. (ENTA) has a market cap of $339.0M and a price-to-sales ratio of 5.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ENTAEnanta Pharmaceuticals, Inc.Follow ENTA — free
—
Price chart with a free account
- Market cap
- 339.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ENTA | 0.3 | — | 2.3 | — | -10.9% | +0.7% | -90% | -115% |
| AVTX | 0.4 | — | — | — | — | -87% | — | -43% |
| MPLT | 0.4 | — | — | — | — | — | — | -88% |
| EDIT | 0.4 | — | 4.5 | — | — | +21% | -161% | — |
| FENC | 0.4 | — | 5.3 | — | — | +78% | -2% | -94% |
| RLMD | 0.3 | — | — | — | -13.2% | — | — | -62% |
| CAPR | 0.3 | — | — | — | — | — | — | -88% |
| KYTX | 0.3 | — | — | — | — | — | — | -110% |
| AVIR | 0.3 | — | 0.3 | — | — | — | — | -91% |
| ZURA | 0.3 | — | — | — | — | — | — | — |
| XFOR | 0.3 | — | 12.8 | — | — | -52% | — | -237% |
| Median of these 10 | — | 4.9 | — | -13.2% | -15% | -82% | -89% |
; EV/Sales 2.3 vs. 4.9.
Growth vs. price
each dot a company · hover or tap for valuesEnanta Pharmaceuticals, Inc. — questions
- What is Enanta Pharmaceuticals, Inc.'s market cap?
- $339.0M.
- What is Enanta Pharmaceuticals, Inc.'s price-to-sales ratio?
- 5.2.
Every figure on this page comes from Enanta Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.